Viatris to make $1.65B Pacira acquisition, adding to momentum in pain
Viatris, a generics and branded medicines maker, is buying into non-opioid pain drugs with a cash acquisition of commercial-stage Pacira BioSciences. The Thursday morning deal, valued at $1.65 billion, follows a ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.